Engagement has recently been established as a key concept
within clinical trials. This trend has delivered a multitude of
benefits for participants, who, rather than being unconnected
from the trial between site visits, now engage in a continual
technology-enabled dialogue with their study. However,
the industry has overlooked the potential for engagement
technologies to benefit two other key stakeholders: sponsors

and CROs. Chris Watson at Exco InTouch explains how
technological framework has the potential to end the uneven
distribution of benefits unlocked by clinical trial engagement
technologies.